Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive Esophagitis (OMAREE)

AstraZeneca

Status: Completed

Conditions: Reflux Esophagitis

Study type: Observational

Funder types: Industry

Identifiers

NCT00859287

NIS-GJP-DUM-2007/1

Details and patient eligibility

About

This open label, non-interventional study is to compare the efficacy of Omepral® tablet and any other treatments excepting proton pump inhibitors (PPIs) for the treatment of various type of acid reflux related symptoms in patients with reflux esophagitis.

Enrollment: 10,703 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients newly diagnosed as erosive esophagitis or history of erosive esophagitis confirmed by endoscopy.
• Patients who answered questionnaires of quality of life (QOLRAD-J), symptom severity and frequency and treatment satisfaction.
• During the past 1 week , patients who have either two days or more with heartburn or acid taste in the mouth of any severity

Exclusion criteria

• Patients receiving treatment with proton pump inhibitors, which make stomach acid decreased during the last 4 weeks prior to enrolment.
• Patients who cannot answer questionnaires of quality of life (QOLRAD-J), symptom severity and frequency and treatment satisfaction.
• Patients included previously in this study.